It is reported that CBR activation could abate cancer progression [9,10], and thus CBR is utilized as a target for anti-carcinogenic therapy in multifarious types of cancer including human non-small lung cancer, glioma cancer, bladder cancer, breast cancer, prostate cancer, and so on [11–13]. This evidence concerns the gene CNR1 and prostate cancer.